Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Sauerland

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.
Blood|July 21, 2012
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Bernhard Heilmeier, Katrin E Edmaier, et al.
Haematologica|June 16, 2018
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or olderVictoria V Prassek, Maja Rothenberg-Thurley, Maria C Sauerland, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Leukemia|August 15, 2000
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative GroupE Lengfelder, A Reichert, C Schoch, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Blood Advances|October 20, 2018
Genetic heterogeneity of cytogenetically normal AML with mutations of <i>CEBPA</i>Nikola P Konstandin, Friederike Pastore, Tobias Herold, et al.
British Journal of Haematology|July 17, 2023
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcomeFriederike Pastore, Hanna Gittinger, Susanne Raab, et al.
International Journal of Hematology|February 24, 2001
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?T Büchner, W Hiddemann, B Wörmann, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.
Blood|July 21, 2012
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Bernhard Heilmeier, Katrin E Edmaier, et al.
Haematologica|June 16, 2018
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or olderVictoria V Prassek, Maja Rothenberg-Thurley, Maria C Sauerland, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Leukemia|August 15, 2000
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative GroupE Lengfelder, A Reichert, C Schoch, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Blood Advances|October 20, 2018
Genetic heterogeneity of cytogenetically normal AML with mutations of <i>CEBPA</i>Nikola P Konstandin, Friederike Pastore, Tobias Herold, et al.
British Journal of Haematology|July 17, 2023
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcomeFriederike Pastore, Hanna Gittinger, Susanne Raab, et al.
International Journal of Hematology|February 24, 2001
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?T Büchner, W Hiddemann, B Wörmann, et al.
Pageof 7